Centre Hospitalier Annecy Genevois

Research site

France 1 Avenue De L Hopital, Bp 90074 Epagny Metz Tessy, Epagny Metz Tessy, 74374 Pringy, France

30 trials recruiting
Plasma cell myeloma · Chronic myeloid leukaemia · Asthma
Adults and children

About Specializations

Centre Hospitalier Annecy Genevois in Pringy, France specialises in clinical trials of conditions such as Plasma cell myeloma, Chronic myeloid leukaemia, Asthma, Hormone receptor positive HER2 negative breast cancer, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

1 Avenue De L Hopital, Bp 90074 Epagny Metz Tessy, Epagny Metz Tessy74374 PringyFrance

Open in maps ↗

Recruiting now: 30 trials
Conditions studied: 68

More sites in Pringy France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

91 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Budesonide
Sponsor:AstraZeneca AB

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Registered drugNo placebo

Study Comparing FOLFOX (Oxaliplatin, Fluorouracil, Calcium Folinate) to Gemcitabine for Patients with Metastatic Pancreatic Cancer Not Suitable for FOLFIRINOX

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Plasma cell myeloma recurrent

Recruiting

Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma

Registered drugNo placebo

Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Polycythaemia vera+4

Recruiting

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo

Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Contact Research Centre

Asthma

Recruiting

Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

Registered drugNo placebo

Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Omalizumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Colorectal cancer

Recruiting

Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

Registered drugNo placebo

Study on Indocyanine Green for Reducing Leakage in Colorectal Cancer Surgery Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Indocyanine Green
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Staphylococcal infection

Recruiting

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo

Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amikacin Sulfate
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Dermatomyositis

Recruiting

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug

France

Participants:18–64 years
Substances:Baricitinib
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Avelumab
Sponsor:Centre Hospitalier De Versailles

Contact Research Centre

Tumour of ampulla of Vater

Recruiting

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Myocarditis

Recruiting

Study on Colchicine for Reducing Heart Damage in Patients with Acute Myocarditis

Registered drug

Study on Colchicine for Reducing Heart Damage in Patients with Acute Myocarditis

Registered drug

France

Participants:18–64 years
Substances:Colchicine
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites